GenomOncology and the My Cancer Genome team at Vanderbilt-Ingram Cancer Center (VICC) have launched the GO Precision Oncology Platform, a novel tool to help physicians determine the best therapy recommendations for patients based on the genetic profile of the patient's cancer. The tool also makes recommendations regarding open clinical trials for which the patient may qualify. A typical next-generation sequencing test for a patient may identify several mutations that are present in the tumor. The Precision Oncology Platform will make this information more actionable by generating a report of recommendations personalized for the patient based on the patient's unique set of mutations and clinical history.
Use of the clinical decision support tool will be tested first in breast cancer patients at VICC with the goal of expanding to all cancer patients in the future.
The GO Precision Oncology Platform harnesses My Cancer Genome content, including more than 2,100 biomarker-driven clinical trials and relevant disease-specific information about biomarkers and the implications of targeted therapies for those mutations. This content is housed in My Cancer Genome's knowledge base, which is powered by GenomOncology's Knowledge Management System (KMS).
The Precision Oncology Platform will become the centerpiece of a novel health care delivery model known as the Clinical Molecular Oncology Consult Service (CMOCS). With the support of a Susan G. Komen Leadership Grant, Mia Levy, M.D., Ph.D., director of Cancer Health Informatics and Strategy at VICC, collaborated with GenomOncology to design the Precision Oncology Platform.